Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Apogee Therapeutics, Inc.NASDAQ: APGE

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 75.44M shares rose 29.1% year over year, ahead of the +15.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.3% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +29.1% holds above the trailing-twelve-month pace of +15.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
75.44M+8.3% QoQ
Last fiscal yearDec 2025
60.69M+10.0% YoY
LTMJun 2026
66.14M+15.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.1%——
1 year+10.0%——
3-year CAGR+6.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
60.69M USD
Year-over-year change
+10.0%
3-year CAGR
+6.2%

Weighted Avg Shares vs competitors

How APGE compares with its peers on the latest reported figures

  • APGE's LTM Jun 2026 weighted avg shares of 66.14M shares is the 8th highest of the 10 companies compared; the peer median is 91.49M shares.
  • Its year-over-year change of +15.7% is the 5th highest of 10, against a peer median of +15.3%.
  • Over three fiscal years its annual growth of +6.2% compares with a peer median of +13.3%.
APGE Competitors Peer median
Weighted Avg Shares for APGE and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
CNTACentessa Pharmaceuticals plcLTM Mar 2026139.28M +13.5%+13.3%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
CGONCG Oncology, Inc. Common stockLTM Sep 202684.72M +15.3%+5.1%
APGEApogee Therapeutics, Inc.LTM Jun 202666.14M +15.7%+6.2%
CELCCelcuity Inc.LTM Jun 202651.65M +19.9%+50.5%
IRONDisc Medicine, Inc.LTM Sep 202637.84M +13.4%+223.8%
Peer median (excluding APGE) 91.49M+15.3%+13.3%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0001.42M
Gross Profit000(1.42M)
Gross Margin————
Research & Development27.79M68.42M167.87M214.71M
Selling, General & Admin2.94M24.58M49.01M70.88M
Operating Expenses30.73M93M216.87M284.18M
Depreciation & Amortization09.02M189K1.42M
EBITDA(39.79M)(74.97M)(181.94M)(254.15M)
EBITDA Margin————
Operating Income(30.73M)(93M)(216.87M)(285.6M)
Operating Margin————
Interest Income92K9.02M34.74M30.03M
Interest Expense9.15M000
Other Income / Expenses(9.06M)9.02M34.74M30.03M
Income Before Tax(39.79M)(83.99M)(182.13M)(255.57M)
Pre-Tax Margin————
Income Tax Expense0018K278K
Net Income(39.79M)(83.99M)(182.15M)(255.84M)
Net Margin————
EPS (Basic)(0.79)(1.66)(3.30)(4.22)
EPS (Diluted)(0.79)(1.66)(3.30)(4.22)
Weighted Avg Shares50.67M50.66M55.19M60.69M
Weighted Avg Shares (Diluted)50.67M50.66M55.19M60.69M

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.